Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset
Identifieur interne : 004024 ( Main/Exploration ); précédent : 004023; suivant : 004025Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset
Auteurs : Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimée [Belgique] ; Henrik Klitgaard [Belgique]Source :
- Movement Disorders [ 0885-3185 ] ; 2003-11.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects), Animal, Animal model, Animals, Anticonvulsant, Anticonvulsants (pharmacology), Anticonvulsants (therapeutic use), Antiparkinson Agents (adverse effects), Antiparkinson agent, Callithrix, Chemotherapy, Combined treatment, Dopamine Agents (adverse effects), Dopamine Agents (metabolism), Drug Synergism, Drug Therapy, Combination, Dyskinesia, Female, Indoles (adverse effects), Levetiracetam, Levodopa, Levodopa (adverse effects), L‐dopa, Male, Monkey, Parkinson disease, Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (metabolism), Piracetam (analogs & derivatives), Piracetam (pharmacology), Piracetam (therapeutic use), Ropinirole, dyskinesia, neuronal firing patterns, ropinirole, synchronization.
- MESH :
- chemical , adverse effects : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Antiparkinson Agents, Dopamine Agents, Indoles, Levodopa.
- chemical , analogs & derivatives : Piracetam.
- chemical , metabolism : Dopamine Agents.
- chemical , pharmacology : Anticonvulsants, Piracetam.
- chemical , therapeutic use : Anticonvulsants, Piracetam.
- chemically induced : Parkinsonian Disorders.
- drug therapy : Parkinsonian Disorders.
- metabolism : Parkinsonian Disorders.
- Animals, Callithrix, Drug Synergism, Drug Therapy, Combination, Female, Male.
Abstract
Long‐term dopamine replacement therapy of Parkinson's disease leads to the occurrence of dyskinesias. Altered firing patterns of neurons of the internal globus pallidus, involving a pathological synchronization/desynchronization process, may contribute significantly to the genesis of dyskinesia. Levetiracetam, an antiepileptic drug that counteracts neuronal (hyper)synchronization in animal models of epilepsy, was assessed in the MPTP–lesioned marmoset model of Parkinson's disease, after coadministration with (1) levodopa (L‐dopa) or (2) ropinirole/L‐dopa combination. Oral administration of levetiracetam (13–60 mg/kg) in combination with either L‐dopa (12 mg/kg) alone or L‐dopa (8 mg/kg)/ropinirole (1.25 mg/kg) treatments was associated with significantly less dyskinesia, in comparison to L‐dopa monotherapy during the first hour after administration. Thus, new nondopaminergic treatment strategies targeting normalization of abnormal firing patterns in basal ganglia structures may prove useful as an adjunct to reduce dyskinesia induced by dopamine replacement therapy without affecting its antiparkinsonian action. © 2003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10542
Affiliations:
- Belgique, Canada, France, Royaume-Uni
- Angleterre, Grand Manchester
- Bordeaux, Manchester
- Université de Manchester
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002C59
- to stream Istex, to step Curation: 002C59
- to stream Istex, to step Checkpoint: 002954
- to stream PubMed, to step Corpus: 003638
- to stream PubMed, to step Curation: 003638
- to stream PubMed, to step Checkpoint: 003716
- to stream Ncbi, to step Merge: 000C26
- to stream Ncbi, to step Curation: 000C26
- to stream Ncbi, to step Checkpoint: 000C26
- to stream Main, to step Merge: 005C47
- to stream PascalFrancis, to step Corpus: 002279
- to stream PascalFrancis, to step Curation: 000A42
- to stream PascalFrancis, to step Checkpoint: 002391
- to stream Main, to step Merge: 005F37
- to stream Main, to step Curation: 004024
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset</title><author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name></author><author><name sortKey="Mcguire, Steven G" sort="Mcguire, Steven G" uniqKey="Mcguire S" first="Steven G." last="Mcguire">Steven G. Mcguire</name></author><author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name></author><author><name sortKey="Michel, Ann" sort="Michel, Ann" uniqKey="Michel A" first="Ann" last="Michel">Ann Michel</name></author><author><name sortKey="Grimee, Renee" sort="Grimee, Renee" uniqKey="Grimee R" first="Renee" last="Grimée">Renee Grimée</name></author><author><name sortKey="Klitgaard, Henrik" sort="Klitgaard, Henrik" uniqKey="Klitgaard H" first="Henrik" last="Klitgaard">Henrik Klitgaard</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1E83D015CA47BC97290431270CF709FDD67F8EF0</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/mds.10542</idno><idno type="url">https://api.istex.fr/document/1E83D015CA47BC97290431270CF709FDD67F8EF0/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002C59</idno><idno type="wicri:Area/Istex/Curation">002C59</idno><idno type="wicri:Area/Istex/Checkpoint">002954</idno><idno type="wicri:doubleKey">0885-3185:2003:Hill M:novel:antiepileptic:drug</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:14639671</idno><idno type="wicri:Area/PubMed/Corpus">003638</idno><idno type="wicri:Area/PubMed/Curation">003638</idno><idno type="wicri:Area/PubMed/Checkpoint">003716</idno><idno type="wicri:Area/Ncbi/Merge">000C26</idno><idno type="wicri:Area/Ncbi/Curation">000C26</idno><idno type="wicri:Area/Ncbi/Checkpoint">000C26</idno><idno type="wicri:doubleKey">0885-3185:2003:Hill M:novel:antiepileptic:drug</idno><idno type="wicri:Area/Main/Merge">005C47</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:04-0130805</idno><idno type="wicri:Area/PascalFrancis/Corpus">002279</idno><idno type="wicri:Area/PascalFrancis/Curation">000A42</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002391</idno><idno type="wicri:doubleKey">0885-3185:2003:Hill M:novel:antiepileptic:drug</idno><idno type="wicri:Area/Main/Merge">005F37</idno><idno type="wicri:Area/Main/Curation">004024</idno><idno type="wicri:Area/Main/Exploration">004024</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset</title><author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Basal Gang, CNRS UMR 5543, Universite Victor Segalen, Bordeaux</wicri:regionArea><placeName><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Mcguire, Steven G" sort="Mcguire, Steven G" uniqKey="Mcguire S" first="Steven G." last="Mcguire">Steven G. Mcguire</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Michel, Ann" sort="Michel, Ann" uniqKey="Michel A" first="Ann" last="Michel">Ann Michel</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>UCB S.A., Pharma Sector, Preclinical CNS Research</wicri:regionArea><wicri:noRegion>Preclinical CNS Research</wicri:noRegion></affiliation></author><author><name sortKey="Grimee, Renee" sort="Grimee, Renee" uniqKey="Grimee R" first="Renee" last="Grimée">Renee Grimée</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>UCB S.A., Pharma Sector, Preclinical CNS Research</wicri:regionArea><wicri:noRegion>Preclinical CNS Research</wicri:noRegion></affiliation></author><author><name sortKey="Klitgaard, Henrik" sort="Klitgaard, Henrik" uniqKey="Klitgaard H" first="Henrik" last="Klitgaard">Henrik Klitgaard</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>UCB S.A., Pharma Sector, Preclinical CNS Research</wicri:regionArea><wicri:noRegion>Preclinical CNS Research</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2003-11">2003-11</date><biblScope unit="vol">18</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1301">1301</biblScope><biblScope unit="page" to="1305">1305</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1E83D015CA47BC97290431270CF709FDD67F8EF0</idno><idno type="DOI">10.1002/mds.10542</idno><idno type="ArticleID">MDS10542</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects)</term><term>Animal</term><term>Animal model</term><term>Animals</term><term>Anticonvulsant</term><term>Anticonvulsants (pharmacology)</term><term>Anticonvulsants (therapeutic use)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson agent</term><term>Callithrix</term><term>Chemotherapy</term><term>Combined treatment</term><term>Dopamine Agents (adverse effects)</term><term>Dopamine Agents (metabolism)</term><term>Drug Synergism</term><term>Drug Therapy, Combination</term><term>Dyskinesia</term><term>Female</term><term>Indoles (adverse effects)</term><term>Levetiracetam</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>L‐dopa</term><term>Male</term><term>Monkey</term><term>Parkinson disease</term><term>Parkinsonian Disorders (chemically induced)</term><term>Parkinsonian Disorders (drug therapy)</term><term>Parkinsonian Disorders (metabolism)</term><term>Piracetam (analogs & derivatives)</term><term>Piracetam (pharmacology)</term><term>Piracetam (therapeutic use)</term><term>Ropinirole</term><term>dyskinesia</term><term>neuronal firing patterns</term><term>ropinirole</term><term>synchronization</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Antiparkinson Agents</term><term>Dopamine Agents</term><term>Indoles</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Piracetam</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anticonvulsants</term><term>Piracetam</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term><term>Piracetam</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Callithrix</term><term>Drug Synergism</term><term>Drug Therapy, Combination</term><term>Female</term><term>Male</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animal</term><term>Anticonvulsivant</term><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Dyskinésie</term><term>Lévodopa</term><term>Lévétiracétam</term><term>Modèle animal</term><term>Parkinson maladie</term><term>Ropinirole</term><term>Singe</term><term>Traitement associé</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Long‐term dopamine replacement therapy of Parkinson's disease leads to the occurrence of dyskinesias. Altered firing patterns of neurons of the internal globus pallidus, involving a pathological synchronization/desynchronization process, may contribute significantly to the genesis of dyskinesia. Levetiracetam, an antiepileptic drug that counteracts neuronal (hyper)synchronization in animal models of epilepsy, was assessed in the MPTP–lesioned marmoset model of Parkinson's disease, after coadministration with (1) levodopa (L‐dopa) or (2) ropinirole/L‐dopa combination. Oral administration of levetiracetam (13–60 mg/kg) in combination with either L‐dopa (12 mg/kg) alone or L‐dopa (8 mg/kg)/ropinirole (1.25 mg/kg) treatments was associated with significantly less dyskinesia, in comparison to L‐dopa monotherapy during the first hour after administration. Thus, new nondopaminergic treatment strategies targeting normalization of abnormal firing patterns in basal ganglia structures may prove useful as an adjunct to reduce dyskinesia induced by dopamine replacement therapy without affecting its antiparkinsonian action. © 2003 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Belgique</li><li>Canada</li><li>France</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Manchester</li></region><settlement><li>Bordeaux</li><li>Manchester</li></settlement><orgName><li>Université de Manchester</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name></region><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name><name sortKey="Mcguire, Steven G" sort="Mcguire, Steven G" uniqKey="Mcguire S" first="Steven G." last="Mcguire">Steven G. Mcguire</name></country><country name="France"><noRegion><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Michel, Ann" sort="Michel, Ann" uniqKey="Michel A" first="Ann" last="Michel">Ann Michel</name></noRegion><name sortKey="Grimee, Renee" sort="Grimee, Renee" uniqKey="Grimee R" first="Renee" last="Grimée">Renee Grimée</name><name sortKey="Klitgaard, Henrik" sort="Klitgaard, Henrik" uniqKey="Klitgaard H" first="Henrik" last="Klitgaard">Henrik Klitgaard</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004024 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004024 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1E83D015CA47BC97290431270CF709FDD67F8EF0
|texte= Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset
}}
| This area was generated with Dilib version V0.6.23. |  |